Skip to main content

Bangalore scientists develop new TB drug regimen with better outcomes, lower toxicity

Tuberculosis causes 250,000 deaths in India each year

Researchers at the Indian Institute of Science (IIS) have discovered a new drug combination that promises better outcome in treating Tuberculosis (TB), which causes 250,000 deaths in India each year.

Animal studies on mice shows that the drug Pranlukast (PRK) not only killed tuberculosis bacteriumbut also compromised its survival strategies within the cells, said the research, published in the February issue of online journal, EMBO Molecular Medicine.

"The problem with TB is the bacterium keeps developing resistance against new drugs and at least 15 drugs have been abandoned so far, either due to resistance against the drug or severe toxicity," says Dr Avdhesha Suroli, lead researcher of the project.

"Our research has proved this combination could work better and be an effective addition to the TB drug pipeline that needs to be reinvented frequently. We need the government or pharma companies to come forward and conduct Phase II trials to know the efficacy and dosage escalation," said Dr Suroli, who led the six-member team that has been working on the project for the past five years.

The researchers propose a combination of Pranlukast with the standard-of-care therapy drugs, to be highly efficient against Tb pathogen, thereby providing an opportunity to use this novel drug combination for TB therapeutics.

"Three drugs are currently being used — Isoniazid, Rifampin and Ethambutol -- in combination therapy and we recommend Ethambutol be replaced with PRK as it could work better," says Dr Suroli.

PRK has the potential to be included directly into the therapeutic regime against Tb as it has approval for treatment of asthma in the US, Japan and Europe.

Although the past decade has seen major developments in the TB drug discovery pipeline, there is a constant need for improved therapeutic interventions.

Continue reading here.

ᐧ

Comments

Post a Comment

Popular posts from this blog

Isotretinoin in India: A tragedy in the offing

Isotretinoin in India: A tragedy in the offing Wednesday, March 28, 2007 08:00 IST  Seema Thakral Isotretinoin is the drug of choice for severe calcitrant cystic acne vulgaris, which often causes scarring and depression from disfigurement. Isotretinoin has been called "the greatest medical advance of the 1980's." A majority of patients with acne are permanently cleared after a four to five months course of treatment. It has also been used off-label for a variety of oncology uses including: cervical cancer, head and neck cancer, squamous cell cancer of the skin, juvenile chronic myelogenous leukemia (CML), and neuroblastoma. However, the drug is a proved teratogen and carries a significant risk of birth defects, if it taken during pregnancy. Birth defects, which have been documented following isotretinoin exposure include abnormalities of the face, eyes, ears, skull, central nervous system, cardiovascular system, and thymus and parathyroid glands. There is an increased ris...
Post a Comment
Read more

Combination Vaccine for Kids withdrawn

A vaccine that combines conventional MMR (Measles, Mumps, Rubella) with Chikenpox has been withdrawn in the United States due to a higher rate of seizures in children. In a study children aged 12 to 23 months who received the combined MMR cum Chickenpox vaccine had double the rate of seizures compared to children who got separate vaccine for MMR and chickenpox. This equates to one additional case of convulsion per 2000 vaccinations.
Post a Comment
Read more

BE guidelines regarding investigator

BE guidelines recommend investigator should possess appropriate medical qualification, experience for conducting pharmacokinetic studies Can chairperson of EC directly write to sponsor to clarify some of the queries of clinical trial raised in EC meeting? Dr. Sreevatsa Please see an extract from FDA's comment on IRB-sponsor relationship. The interrelationship and interaction between the research sponsor (e.g., drug, biologic and device manufacturers), the clinical investigator and the Institutional Review Board (IRB) may be very complex. The regulations do not prohibit direct sponsor-IRB contacts, although, the sponsor-IRB interaction customarily occurs through the investigator who conducts the clinical study. The clinical investigator generally provides the communication link between the IRB and the sponsor. Such linkage is agreed to by the sponsors and investigators when they sign forms FDA-1571 and FDA-1572, respectively, for drug and biologic studies or a...
Post a Comment
Read more